- Approval Id
- 8d63321f7399b3f1
- Drug Name
- VERQUVO FILM-COATED TABLET 2.5MG
- Product Name
- VERQUVO FILM-COATED TABLET 2.5MG
- Approval Number
- SIN16343P
- Approval Date
- 2021-10-01
- Registrant
- BAYER (SOUTH EAST ASIA) PTE LTD
- Licence Holder
- BAYER (SOUTH EAST ASIA) PTE LTD
- Drug Type
- Therapeutic
- Forensic Classification
- Prescription Only
- Dosage Form
- TABLET, FILM COATED
- Dosage
- **2\. DOSAGE AND ADMINISTRATION**
Before starting VERQUVO, care should be taken to optimise volume status and diuretic therapy, as well as other guideline-directed heart failure therapies, to stabilise patients after the decompensation event, particularly in patients with very high NT-proBNP levels _\[see 9. CLINICAL STUDIES_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_ _\]_.
**2.1 Adults**
- The recommended starting dose of VERQUVO is 2.5 mg once daily, taken with food.
- Double the dose of VERQUVO approximately every 2 weeks to reach the target maintenance dose of 10 mg once daily, as tolerated by the patient.
- For patients who are unable to swallow whole tablets, VERQUVO may be crushed and mixed with water immediately before administration _\[see 10. CLINICAL PHARMACOLOGY, 10.4 Pharmacokinetics_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_ _\]_.
Missed Dose
If a dose is missed, it should be taken as soon as the patient remembers on the same day of the missed dose. Patients should not take two doses of VERQUVO on the same day.
**2.2 Pediatric Patients**
Safety and efficacy of VERQUVO have not been established in patients less than 18 years of age _\[see 6. USE IN SPECIFIC POPULATIONS, 6.3 Pediatric Use and 10. CLINICAL PHARMACOLOGY, 10.4 Pharmacokinetics_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_ _\]_.
**2.3 Geriatric Patients**
No dosage adjustment of VERQUVO is required for geriatric patients _\[see 6. USE IN SPECIFIC POPULATIONS, 6.4 Geriatric Use and 10. CLINICAL PHARMACOLOGY, 10.4 Pharmacokinetics_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_ _\]_.
**2.4 Renal Impairment**
No dose adjustment of VERQUVO is required in patients with estimated glomerular filtration rate (eGFR) ≥15 mL/min/1.73m2 (without dialysis). VERQUVO has not been studied in patients with eGFR <15 mL/min/1.73m2 at treatment initiation or on dialysis and is therefore not recommended in these patients _\[see 6. USE IN SPECIFIC POPULATIONS, 6.5 Renal Impairment, 9. CLINICAL STUDIES, and 10. CLINICAL PHARMACOLOGY, 10.4 Pharmacokinetics_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_ _\]_.
**2.5 Hepatic Impairment**
No dose adjustment of VERQUVO is required in patients with mild or moderate hepatic impairment. VERQUVO has not been studied in patients with severe hepatic impairment and is therefore not recommended in these patients _\[see 6. USE IN SPECIFIC POPULATIONS, 6.6 Hepatic Impairment and 10. CLINICAL PHARMACOLOGY, 10.4 Pharmacokinetics_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_ _\]_.
- Route Of Administration
- ORAL
- Indication Info
- **1\. INDICATIONS AND USAGE**
VERQUVO (vericiguat) is indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction, who are stabilised after a recent decompensation event requiring IV therapy. Vericiguat is administered in combination with other HF therapies _\[see 9. CLINICAL STUDIES_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_ _\]_.
- Contraindications
- **3\. CONTRAINDICATIONS**
VERQUVO is contraindicated in patients with concomitant use of other soluble guanylate cyclase (sGC) stimulators, such as riociguat _\[see 5. DRUG INTERACTIONS AND OTHER FORMS OF INTERACTIONS, 5.2 Other Soluble Guanylate Cyclase Stimulators_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_ _\]_.
Hypersensitivity to the active substance or to any of the excipients listed in section _14.2 Composition_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_.
- Atc Code
- C01DX22
- Atc Item Name
- vericiguat
- Pharma Manufacturer Name
- BAYER (SOUTH EAST ASIA) PTE LTD
- Company Detail Path
- /organization/cdf0085bd222bf2a/bayer-south-east-asia-pte-ltd
